Management of Alcohol Withdrawal Syndrome with Diazepam
Dosing and Duration Guidelines
- The American Society of Addiction Medicine recommends avoiding benzodiazepine use beyond 10-14 days due to potential for abuse and dependence 1
- For mild to moderate withdrawal, diazepam can be administered at 5-10 mg every 6-8 hours, with dosing adjusted based on symptom severity 2
Monitoring and Assessment
- The Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale should be used to assess withdrawal severity; scores >8 indicate moderate withdrawal and ≥15 indicate severe withdrawal 1
- A symptom-triggered regimen is preferred over fixed-dose schedule to prevent medication accumulation 1
- Regular monitoring of vital signs, mental status, and withdrawal symptoms is essential during treatment 1
Treatment Setting Considerations
- Patients at risk of severe withdrawal should preferably be managed in an inpatient setting 3
- Inpatient treatment should be considered for patients with significant medical or psychiatric comorbidities 1
- Inpatient treatment should be considered for patients with failed outpatient treatment 1
- Inpatient treatment should be considered for patients with high levels of recent drinking 1
Special Considerations
- All patients receiving diazepam for alcohol withdrawal should be given thiamine supplementation (100-300 mg/day) to prevent Wernicke encephalopathy 1, 2
- Thiamine should be administered before giving any glucose-containing fluids 1
- For patients with liver dysfunction, advanced age, or respiratory issues, lorazepam (1-4 mg every 4-8 hours) should be considered instead of diazepam 1, 2
- Psychoactive medications used for alcohol withdrawal should be dispensed in small quantities or each dose supervised to reduce risk of misuse 3
Common Pitfalls and Caveats
- Extending benzodiazepine treatment beyond the recommended 7-10 days increases risk of dependence and should be avoided 1
- Inadequate dosing may lead to breakthrough symptoms including seizures and delirium tremens 2
- Excessive dosing can cause respiratory depression, especially in patients with underlying pulmonary conditions 2